Dr. McCurdy discusses treating MDS (myelodysplastic syndromes) with combination therapies including the latest treatment options available and promising clinical trials and research.
Rare blood cancer and bone marrow failure diseases are often difficult to diagnose and even harder to explain. AAMDSIF brings international experts to your computer, tablet or smartphone using language that is easy to understand in a convenient one hour format. We have hundreds of webinars available for you to watch at any time you want!
|Tuesday, March 9, 2021 - 5:30pm||ASH 2020: MDS and AML Updates for Patients|
|Thursday, March 18, 2021 - 2:00pm||COVID-19 Update: Vaccinations for Bone Marrow Failure Patients|
|Monday, March 22, 2021 - 12:00pm||New Transplant Advances for Patients|
|Friday, April 23, 2021 - 2:00pm||Intimacy and Bone Marrow Failure|
|Tuesday, April 27, 2021 - 2:00pm||Haploidentical Transplant for MDS|
Sarah Bannon is a Senior Genetic Counselor in the Department of Clinical Cancer Genetics at the UT MD Anderson Cancer Center. Her clinical responsibilities include providing risk assessment and genetic counseling services to individuals at risk for an inherited predisposition to hematologic malignancies (leukemia). She is the Genetic Counselor for the Hereditary Hematologic Malignancies Clinic (HHMC).
In this webinar, Ms. Bannon discusses hereditary or genetic predisposition to having MDS.
Olatoyosi Sobulo Odenike, MD, is Professor of Medicine in the Section of Hematology/Oncology and Director of the Leukemia Program at the University of Chicago as well as Co-Chair of the AAMDSIF Medical Advisory Board. Dr. Odenike is an expert in the care of adults with leukemia, chronic myeloproliferative diseases, and myelodysplastic syndromes. An active researcher, Dr. Odenike is involved in the development of novel therapeutic agents for the treatment of acute and chronic leukemias and chronic myeloproliferative diseases. The ultimate goal of her research is to improve treatment options for patients with these diseases. Dr. Odenike is the principal investigator on a number of clinical trials investigating molecularly targeted agents in this patient population. These clinical trials also integrate laboratory studies to evaluate the effect that these agents have on cancer cells.
Dr. Gowin discusses the critical aspects of living well with the overlapping diagnosis of MDS and MPNs. Her presentation includes a scientific assessment of interventions including nutrition, supplements, exercise and meditation.
Due to internet connectivity issues, the audio for this webinar will be rerecorded as soon as the speaker is available. In the interim, please accept our apologies for the quality of the sound. We are attached a PDF of the presentation for your review although we note that the video quality was acceptable.
Timothy S. Olson, MD, PhD, is an Attending Physician with Children's Hospital of Philadelphia where he serves as the Medical Director of the Blood and Bone Marrow Transplant Program and as Director of Research for the Comprehensive Bone Marrow Failure Center. Dr. Olson is also an Assistant Professor of Pediatrics at the Perelman School of Medicine at The University of Pennsylvania. Dr. Olson focuses on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure.
Michael Keng, M.D. is an Assistant Professor and holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital. His clinical areas of interest are: myelodysplastic syndromes, myeloproliferative disorders, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoid leukemia, and aplastic anemia. Dr. Keng provides a overview of the current treatment strategies for high risk MDS (myelodysplastic syndromes) patients and answers patient questions at the end of the presentation. Please note that this presentation is runs longer than most AAMDSIF webinars (1 hour, 27 minutes).
Ilene Weitz, MD, is an assistant professor of clinical medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology. This webinar focuses on the latest in research presented at the 2019 American Society of Hematology (ASH) Annual Meeting held at the end of 2019. Dr. Weitz has selected a number of abstracts (research summaries) and provides a high level assessment of new and ongoing research into treating aplastic anemia and/or PNH. Participants were able to submit questions during the presentation and Dr. Weitz' responses are at the end of the webinar recording.
Mikkael Sekeres, MD, MS discusses issues related to the impact of COVID-19 on the care of bone marrow failure patients including the importance of patients remaining at home even as more areas reduce restrictions, adapting to telemedicine, and resuming treatments that may have been delayed.
Dr. Mesa discusses the overlap between MDS (myelodysplastic sydromes) and MPNs (myeloproliferative neoplasms), including diagnosis and treatment options including the latest in clinical trials. He also provides an update on the impact of COVID-19 on patients with MDS/MPNs overlap syndrome.
This webinar is an excerpt from a longer webinar entitled "Understanding the Overlap between MDS and MPNs" and has been edited accordingly. Dr. Mesa gives an overview of the specific concerns that patients with the overlapping conditions of MDS and MPNs have related to the coronavirus (COVID-19) pandemic.
Rami Komrokji, MD, of Moffitt Cancer Center in Tampa, Florida, addresses the concerns of low-risk MDS patients and their caregivers and reviews the precautions they should be taking to protect their health during the COVID-19 pandemic. The webinar recording features patient-submitted questions.
Twyla Jackson, RDN, LDN, CNSC, Northside Cancer Center, Atlanta, provides an overview of the dietary and nutritional concerns facing patients, families and caregivers dealing with bone marrow failure disease. Ms. Jackson provides evidence-based, scientifically accurate guidance including specific concerns related to potential interactions between certain treatment medications and specific foods. She also provides important information on the use of supplements and a healthy, active lifestyle. Ms. Jackson works closely with hematologists and oncologists in her role at Northside Cancer Center in Atlanta and this presentation includes specific questions from patients at the end.
Hemant Murthy, MD, Mayo Clinic Jacksonville, Florida, provides a comprehensive overview of the risks and benefits of bone marrow transplant for patients with bone marrow failure disease including aplastic anemia, PNH, MDS and AML. This sessions includes a review of the generalized criteria for eligibility, the potential complications of transplant and long-term outcomes based on ongoing studies. Dr. Murthy also offers hopeful news for older patients who may have thought they were not eligible for transplant but with new treatment protocols may be able to at least consider this option. Dr. Murthy answered a number of patient-submitted questions at the end of the presentation.
Jamile Shammo, MD, FASCP, FACP, Rush University, Chicago, provides an update on the latest in diagnosing and treating PNH including a discussion about Soliris and Ultomiris as well as several new treatments that are in clinical trials and are showing promise for patients with this rare disease. Dr. Shammo also answered a number of patient-submitted questions.
Daniel Pollyea, MD, MS, University of Colorado Health, gives a comprehensive overview of what happens when a higher risk MDS patient transitions to AML including the diagnositic criteria, treatment options and outcomes assessments. Dr. Pollyea also reviews some of the most promising treatment options that are in clinical trial and/or new to the treatment space. He also discusses the increasing success rates for older patients who go to transplant as a curative treatment for High Risk MDS and AML. Dr. Pollyea answers a number of patient-submitted questions as well.
Rami Komrokji, MD, Moffitt Cancer Center, Florida, provides a comprehensive overview of lower risk MDS from diagnosis to treatment. Dr. Komrokji focuses on how hematologists and oncologists use different tools to assess the risk for patients when diagnosed with MDS including an overview of IPSS-R. He also explains how this assessment tool is only useful prior to treatment and that after interventions, other assessment tools are used by healthcare professionals to provide guidance and support to patients, families and caregivers. Dr. Komrokhi further discusses the treatment landscape including the newly announced luspatercept and several prospective treatments in the pipeline/clinical trial phase.
Veronica Dioverti Prono, MD, Johns Hopkins School of Medicine , Baltimore, provides an update on the COVID-19 (novel coronavirus) pandemic as it relates to patients, families and caregivers dealing with bone marrow failure disease. Dr. Prono gives practical advise on how to avoid exposure to the virus and answers questions from a live audience.